| Literature DB >> 35782520 |
Elisa Assirelli1, Paolo Caravaggi2, Antonio Mazzotti3, Francesco Ursini4,5, Alberto Leardini2, Claudio Belvedere2, Simona Neri1.
Abstract
Objective: Osteoarthritis (OA) is a multifactorial musculoskeletal disorder affecting mostly weight-bearing joints. Chondrocyte response to load is modulated by inflammatory mediators and factors involved in extracellular cartilage matrix (ECM) maintenance, but regulatory mechanisms are not fully clarified yet. By using a recently proposed experimental model combining biomechanical data with cartilage molecular information, basally and following ex-vivo load application, we aimed at improving the understanding of human cartilage response to cyclic mechanical compressive stimuli by including cartilage original anatomical position and OA degree as independent factors.Entities:
Keywords: knee biomechanics; knee cartilage; knee compartments; knee loading; osteoarthritis
Year: 2022 PMID: 35782520 PMCID: PMC9240619 DOI: 10.3389/fbioe.2022.862254
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1(A) Cartilage explants from four representative donors. Images of surgical samples are shown. Condyles were divided in zones (anterior, posterior, medial, and lateral) and in areas with different macroscopic scores (from 0 to 4). (B) Each area was independently cored to obtain cartilage cylinders placed inside compression plates and exposed to unconfined compression in the Flexcell bioreactor apparatus.
Cartilage markers analysed for their gene expression or as soluble factors released in culture supernatants. The main function of each marker in cartilage turnover is reported.
| Markers | Description/role in cartilage biology | References |
|---|---|---|
| COL2A1 | One of the main components of cartilage extracellular matrix, it is fundamental for cartilage structure maintenance |
|
| SOX9 | A transcription factor that regulates the expression of genes including COLIIA1 and ACAN, respectively encoding for COL2A1 and Aggrecan | ( |
| Aggrecan | An extracellular matrix component, it is the most crucial proteoglycan for proper functioning of articular cartilage |
|
| IL-4Rα | IL-4 is an antinflammatory cytokine with a known protective anabolic effect on articular cartilage. It is also involved in mechanotransduction. In osteoarthritic chondrocytes an alteration of the IL-4/IL-4R system is described |
|
| C3 CFB | This two factors, members of the Complement system alternative pathway, contribute to activation of the innate immunity response in OA joints | ( |
| IL-6 | It is a cytokine that strongly activates the immune system and enhances the inflammatory response. Its production in the affected joint is usually in response to IL-1β and TNFα and is mainly implemented by chondrocytes, osteoblasts, fibroblast-like synoviocytes, macrophages, and adipocytes. IL-6 on joint cartilage causes a decrease in the production of type II collagen and increases the production of enzymes from the metalloproteinase group |
|
| IL-8 | This chemokine is an important inflammatory mediator that plays a central role in the onset of inflammatory processes in OA. Increased levels of IL-8 in synovial fluid are associated with pain |
|
| MMP13 | One of the main matrix enzymes involved in cartilage degradation, it is a collagenase responsible of type II collagen cleavage, and it plays a crucial role in OA pathogenesis and progression | ( |
| ADAMTS5 | One of the main matrix enzymes involved in cartilage degradation, it is an aggrecanase also involved in OA cartilage proteoglycan loss |
|
| COMP | A noncollagenous extracellular matrix protein, it is a biomarker of cartilage turnover |
|
| CS | It is an important structural component of cartilage, providing resistance to compression |
|
| PIICP | It is a product of cartilage metabolism, considered as biological marker of collagen II synthesis |
|
| CoL-2CAV | It is a product of cartilage metabolism, considered as biomarker of collagenase cleavage of collagen II |
|
Flowchart of the applied statistical methodology. Main analysis: Generalized Linear Mixed Model (GLMM) with cartilage markers (mRNAs and soluble factors) as Dependent Variables; compression (Compressed-Non Compressed), sample position (anterior-posterior; medial-lateral), compartment (varus-valgus), disease grading (0–1/3–4), ILβ-no ILβ, affected-contralateral as potential Fixed Effects; age, BMI, OA-Grade (Kellgren-Lawrence) as potential covariates; patient, and gender as potential random effects.
|
|
Mono-compartmental knee OA patient characteristics: age at surgery (in years), sex, body mass index (BMI, in kg/m2), radiographic score (Kellgren and Lawrence, 1957) and affected compartment (medial, M, for varus, and lateral L, for valgus knees).
| Age | Sex | BMI | KL | Affected compartment |
|---|---|---|---|---|
| 78 | F | 22.4 | 3 | M |
| 67 | M | 28.4 | 3 | M |
| 76 | F | 25.2 | 3 | M |
| 75 | M | 24.2 | 2 | M |
| 79 | F | — | 4 | L |
| 64 | M | 26.9 | 3 | M |
| 69 | F | 32.9 | 2 | M |
| 80 | F | 26.9 | 3 | L |
| 68 | M | 32 | 3 | M |
| 82 | M | 28.3 | 4 | M |
| 72 | F | 29.1 | 3 | M |
| 66 | F | 37.7 | 2 | L |
| 87 | F | 26.5 | 3 | L |
| 66 | M | 24.4 | 3 | M |
| 80 | M | 26.6 | 3 | L |
| 53 | F | 20.1 | 3 | L |
| 56 | F | 22.9 | 2 | L |
| 61 | M | 28.2 | 4 | M |
| 70 | F | 28.4 | 3 | M |
FIGURE 2Correspondence between macroscopic scores of medial and lateral condylar compartments and varus/valgus condition. According to knee biomechanics, higher scores in medial compartments of varus knees and higher scores in lateral compartments of valgus knees were observed (Mann Whitney U test).
FIGURE 3(A) Microscopic histological score attributio n to condyle areas identified by position (medial, lateral, anterior, posterior) and OA degree (macroscopic score) of a representative knee OA sample. Scale bar: 100 μm; (B) Correlation between macroscopic and microscopic (histopathological) score of 37 condyle areas from 16 donors. Microscopic scores are represented as mean ± SD.
FIGURE 4Effect of compression on SOX9, COL2A1, and Aggrecan gene expression in affected and contralateral compartments (Sidak test for multiple comparisons). Data are represented as medians (number of mRNA molecules of the gene of interest/105 GAPDH copies). Boxes represent 25th-75th percentiles; whiskers represent minimum and maximum values; dots represent outliers. NC= uncompressed; C= compressed; IL-1β= stimulated with 2 mg/ml IL-1β.
FIGURE 5Effect of compression on IL-6 (A) and IL-8 (B) gene expression in affected and contralateral compartments (upper panels). In lower panels, samples are divided according to the original position of the cartilage area (anterior/posterior condyle) (Sidak test for multiple comparisons). Data are represented as medians (number of mRNA molecules of the gene of interest/105 GAPDH copies). Boxes represent 25th–75th percentiles; whiskers represent minimum and maximum values; dots represent outliers. NC= uncompressed; C= compressed; IL-1β= stimulated with 2 mg/ml IL-1β.
FIGURE 6Effect of compression on IL-4Rα (A), C3 (B), and CFB (C) gene expression in affected and contralateral compartments (upper panels). In lower panels, samples are divided according to the original position of the cartilage area (anterior/posterior condyle) (Sidak test for multiple comparisons). Data are represented as medians (number of mRNA molecules of the gene of interest/105 GAPDH copies). Boxes represent 25th–75th percentiles; whiskers represent minimum and maximum values; dots represent outliers. NC, uncompressed; C, compressed; IL-1β, stimulated with 2 mg/ml IL-1β.
FIGURE 7Effect of compression on soluble factor release (A-E) in affected and contralateral compartments (upper panels of each section). In lower panels of each section, samples are divided according to the original position of the cartilage area (anterior/posterior condyle) (Sidak test for multiple comparisons). Data are presented as medians (number of mRNA molecules of the gene of interest/105 GAPDH copies). Boxes represent 25th– 75th percentiles; whiskers represent minimum and maximum values; dots represent outliers. NC, uncompressed; C, compressed; IL-1β, stimulated with 2 mg/ml IL-1β.